Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial

Diabetes, Obesity and Metabolism

Volumn 18, Issue 2, 2016, Pages 169-177

  Heerspink, H J L ^a   Ninomiya, T ^b   Persson, F ^c   Brenner, B M ^d   Brunel, P ^e   Chaturvedi, N ^f   Desai, A S ^d   Haffner, S M ^g   Mcmurray, J J V ^h   Solomon, S D ^d   Pfeffer, M A ^d   Parving, H H ⁱ   de Zeeuw, D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b KYUSHU UNIVERSITY   (Japan)

^c STENO DIABETES CENTER   (Denmark)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Albuminuria; Cardiovascular disease; Chronic kidney disease; Direct renin inhibition; Surrogate endpoint; Type 2 diabetes

Indexed keywords

ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; RENAL PROTECTION; RISK REDUCTION; AGED; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; DOUBLE BLIND PROCEDURE; FOLLOW UP; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; URINE;

ALISKIREN; AMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMARIC ACID DERIVATIVE; RENIN;

AGED; ALBUMINURIA; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN; RISK FACTORS;

EID: 84956898063     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12600     Document Type: Article

References (34)

1. Andresdottir G, Jensen ML, Carstensen B et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 2014; 37: 1660-1667.
2. Association AD. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37: S14-S80.
3. Ninomiya T, Perkovic V, de Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
4. Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-906.
5. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
6. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
7. Roscioni SS, de Zeeuw D, Hellemons ME et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2012; 56: 259-267.
8. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.
9. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261.
10. Holtkamp FA, de Zeeuw D, de Graeff PA et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499.
11. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int 2015; 87: 243-244.
12. de Zeeuw D, Raz I. Albuminuria: a great risk marker, but an underestimated target in diabetes. Diabetes Care 2008; 31(Suppl. 2): S190-S193.
13. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
14. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903.
15. Qaseem A, Hopkins RH, Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 2013; 159: 835-847.
16. Makani H, Bangalore S, Desouza KA et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360.
17. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
18. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
19. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren trial in type 2 Ddabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
20. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
21. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
22. Imai E, Haneda M, Chan JC et al. Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). Nephrol Dial Transplant 2013; 28: 2526-2534.
23. Hallan SI, Ritz E, Lydersen S et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-1077.
24. Van der Velde M, Halbesma N, de Charro FT et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20: 852-862.
25. Smink PA, Lambers Heerspink HJ, Gansevoort RT et al. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis 2010; 60: 804-811.
26. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
27. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
28. European Medicine Agency. European public assessment report Rasilez. EMA 2012. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000780/human_med_001013.jsp&mid=WC0b01ac058001d124. Accessed 1 April 2015.
29. Zoja C, Morigi M, Figliuzzi M et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995; 26: 934-941.
30. Zoja C, Donadelli R, Colleoni S et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998; 53: 1608-1615.
31. Diwakar R, Pearson AL, Colville-Nash P et al. The role played by endocytosis in albumin-induced secretion of TGF-beta1 by proximal tubular epithelial cells. Am J Physiol Renal Physiol 2007; 292: F1464-F1470.
32. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280: F562-F573.
33. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
34. Stehouwer CD, Gall MA, Twisk JW et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.